As noticed in several patients, the use of omalizumab in STAT3-AD-HIES leads to the improvement of skin signs and symptoms, the decrease of serum IgE and the improvement of pulmonary manifestations [52]. This evidence concerns the gene STAT3 and Alzheimer disease.